Treatment of recurrent hepatitis C after liver transplantation with IL-2r Ab.
Pinna
A D
AD
Department of Surgery and Pathology, Liver/GI Transplant Division, Cell Transplant Division and Immunopathology, University of Miami, School of Medicine, Miami, Florida, USA.
Ricordi
C
C
Weppler
D
D
Ruiz
P
P
Tzakis
A G
AG
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D012008:Recurrence
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D000077561:Daclizumab